Physician profile
Roy Vellanki
NPI 1750465811
$4,761.37
in general payments reported to CMS, 2019-2025
21 companies · $732 in 2025
The $732 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $359 · 2021: $901 · 2022: $895 · 2023: $474 · 2024: $468 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $983.91 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $920.32 | 2019-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $644.40 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $492.25 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $395.86 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $301.68 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.45 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $126.38 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $122.83 | 2019-2025 | Spravato |
| Noven Therapeutics, LLC | $118.40 | 2021-2025 | Secuado |
| Neurocrine Biosciences, INC. | $111.23 | 2019-2024 | Ingrezza |
| Abbvie INC. | $53.04 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.48 | 2025 | Cobenfy |
| Corium, LLC | $31.86 | 2024-2025 | Azstarys |
| Indivior INC. | $30.94 | 2022-2023 | Perseris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $28.26 | 2025 | Qelbree |
| Luye Pharma (USA) LTD. | $20.47 | 2025 | Erzofri Extended-Release |
| Eisai INC. | $14.66 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.46 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $13.25 | 2022 | |
| Bausch Health US, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Vellanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.